Literature DB >> 31171510

Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events.

Yoshiaki Abe1,2, Tetsuya Kobayashi3, Kentaro Narita1, Hiroki Kobayashi1, Akihiro Kitadate1, Daisuke Miura1, Masami Takeuchi1, Kosei Matsue1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31171510      PMCID： PMC6560350          DOI： 10.1182/bloodadvances.2019000247

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  12 in total

1.  The natural history of preclinical diastolic dysfunction: a population-based study.

Authors:  Mark W Vogel; Joshua P Slusser; David O Hodge; Horng H Chen
Journal:  Circ Heart Fail       Date:  2012-01-25       Impact factor: 8.790

Review 2.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Sherif F Nagueh; Otto A Smiseth; Christopher P Appleton; Benjamin F Byrd; Hisham Dokainish; Thor Edvardsen; Frank A Flachskampf; Thierry C Gillebert; Allan L Klein; Patrizio Lancellotti; Paolo Marino; Jae K Oh; Bogdan Alexandru Popescu; Alan D Waggoner
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2016-07-15       Impact factor: 6.875

3.  Cardiac and renal complications of carfilzomib in patients with multiple myeloma.

Authors:  Meletios A Dimopoulos; Maria Roussou; Maria Gavriatopoulou; Erasmia Psimenou; Dimitrios Ziogas; Evangelos Eleutherakis-Papaiakovou; Despina Fotiou; Magdalini Migkou; Nikolaos Kanellias; Ioannis Panagiotidis; Argyrios Ntalianis; Elektra Papadopoulou; Kimon Stamatelopoulos; Efstathios Manios; Constantinos Pamboukas; Sofoklis Kontogiannis; Evangelos Terpos; Efstathios Kastritis
Journal:  Blood Adv       Date:  2017-02-27

4.  Cardiotoxicity of the anticancer therapeutic agent bortezomib.

Authors:  Dominika Nowis; Michał Maczewski; Urszula Mackiewicz; Marek Kujawa; Anna Ratajska; Mariusz R Wieckowski; Grzegorz M Wilczyński; Monika Malinowska; Jacek Bil; Pawel Salwa; Marek Bugajski; Cezary Wójcik; Maciej Siński; Piotr Abramczyk; Magdalena Winiarska; Anna Dabrowska-Iwanicka; Jerzy Duszyński; Marek Jakóbisiak; Jakub Golab
Journal:  Am J Pathol       Date:  2010-06       Impact factor: 4.307

5.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Authors:  A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

6.  Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin.

Authors:  Panagiotis Efentakis; Georgios Kremastiotis; Aimilia Varela; Panagiota-Efstathia Nikolaou; Eleni-Dimitra Papanagnou; Constantinos H Davos; Maria Tsoumani; Georgios Agrogiannis; Anastasia Konstantinidou; Efstathios Kastritis; Zoi Kanaki; Efstathios K Iliodromitis; Apostolos Klinakis; Meletios A Dimopoulos; Ioannis P Trougakos; Ioanna Andreadou; Evangelos Terpos
Journal:  Blood       Date:  2018-11-27       Impact factor: 22.113

Review 7.  Pre-clinical diastolic dysfunction.

Authors:  Siu-Hin Wan; Mark W Vogel; Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

8.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

Review 9.  Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Authors:  Ajai Chari; A Keith Stewart; Stuart D Russell; Philippe Moreau; Joerg Herrmann; Jose Banchs; Roman Hajek; John Groarke; Alexander R Lyon; George N Batty; Sunhee Ro; Mei Huang; Karim S Iskander; Daniel Lenihan
Journal:  Blood Adv       Date:  2018-07-10

10.  Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.

Authors:  Mara Gavazzoni; Carlo Mario Lombardi; Enrico Vizzardi; Elio Gorga; Edoardo Sciatti; Laura Rossi; Angelo Belotti; Giuseppe Rossi; Marco Metra; Riccardo Raddino
Journal:  Eur J Pharmacol       Date:  2018-09-07       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.